USE OF 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AS A SOLUBILIZING AND STABILIZING EXCIPIENT FOR PROTEIN DRUGS

被引:138
|
作者
BREWSTER, ME
HORA, MS
SIMPKINS, JW
BODOR, N
机构
[1] UNIV FLORIDA,CTR DRUG DESIGN & DELIVERY,GAINESVILLE,FL 32611
[2] CETUS CORP,EMERYVILLE,CA 94608
[3] UNIV FLORIDA,COLL PHARM,DEPT PHARMACODYNAM,GAINESVILLE,FL 32611
关键词
2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; OVINE GROWTH HORMONE; INTERLEUKIN-2; INSULIN; STABILITY;
D O I
10.1023/A:1015870521744
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A chemically modified, amorphous beta-cyclodextrin, namely, 2-hydroxypropyl-beta-cyclodextrin (HPCD), was examined as a solubilizing and stabilizing agent for protein drugs. The aqueous solubility of ovine growth hormone at pH 7.4 was increased through the use of HPCD. This effect was manifested by higher UV transparency at 600 nm. Interleukin-2 (IL-2) is rendered insoluble upon lyophilization in the absence of stabilizers. Use of aqueous HPCD provides a clear solution, as indicated by fluorometric light scattering, and inhibits aggregate formation, as shown by ultracentrifugation and Western blot analyses. In addition, there were no major conformational changes of IL-2 in HPCD formulation as indicated by fourth-derivative ultraviolet spectroscopy. Finally, IL-2 retained 100% of its biopotency when prepared in HPCD solutions. Aggregation of insulin was also suppressed by HPCD. These data, as well as the i.v. safety of HPCD and its well-characterized chemical composition, suggest that this starch derivative may be a potentially useful excipient for protein drugs intended for parenteral use.
引用
收藏
页码:792 / 795
页数:4
相关论文
共 50 条
  • [1] USE OF 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AS AN INTRATHECAL DRUG VEHICLE WITH OPIOIDS
    JANG, JD
    YAKSH, TL
    HILL, HF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1992, 261 (02): : 592 - 600
  • [2] THE UTILITY OF 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AS A VEHICLE FOR THE INTRACEREBRAL AND INTRATHECAL ADMINISTRATION OF DRUGS
    YAKSH, TL
    JANG, JD
    NISHIUCHI, Y
    BRAUN, KP
    RO, SG
    GOODMAN, M
    LIFE SCIENCES, 1991, 48 (07) : 623 - 633
  • [3] THE USE OF 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AS A VEHICLE FOR INTRAVENOUS ADMINISTRATION OF DEXAMETHASONE IN DOGS
    DIETZEL, K
    ESTES, KS
    BREWSTER, ME
    BODOR, NS
    DERENDORF, H
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 59 (03) : 225 - 230
  • [4] INTERACTIONS BETWEEN PRESERVATIVES AND 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
    LOFTSSON, T
    STEFANSDOTTIR, O
    FRIORIKSDOTTIR, H
    GUOMUNDSSON, O
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1992, 18 (13) : 1477 - 1484
  • [5] 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN COMPLEXATION WITH URSODEOXYCHOLIC ACID
    VANDELLI, MA
    SALVIOLI, G
    MUCCI, A
    PANINI, R
    MALMUSI, L
    FORNI, F
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 118 (01) : 77 - 83
  • [6] THE PREPARATION AND CHARACTERIZATION OF DIGOXIN BETA-CYCLODEXTRIN AND 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN COMPLEX
    HELM, H
    BACKENSFELD, T
    MULLER, BW
    WAALER, T
    ACTA PHARMACEUTICA NORDICA, 1991, 3 (04): : 199 - 204
  • [7] MICROCALORIMETRIC INVESTIGATION OF THE COMPLEXATION BETWEEN 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND AMINE DRUGS WITH THE DIPHENYLMETHYL FUNCTIONALITY
    TONG, WQ
    LACH, JL
    CHIN, TF
    GUILLORY, JK
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (10-12) : 1139 - 1146
  • [8] COMPLEXATION OF VARIOUS FRAGRANCE MATERIALS WITH 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
    MATSUDA, H
    ITO, K
    FUJIWARA, Y
    TANAKA, M
    TAKI, A
    UEJIMA, O
    SUMIYOSHI, H
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1991, 39 (04) : 827 - 830
  • [9] SOLUBILIZATION AND ELECTROCHEMICAL STABILIZATION OF SUBSTITUTED PHENOLS THROUGH THE USE OF 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
    BREWSTER, ME
    BRAUNSTEIN, AJ
    BARTRUFF, MSM
    KIBBEY, C
    HUANG, MJ
    POP, E
    BODOR, N
    SUPRAMOLECULAR CHEMISTRY, 1994, 4 (01) : 69 - 76
  • [10] EFFECTS OF 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN ON THE AQUEOUS SOLUBILITY OF DRUGS AND TRANSDERMAL DELIVERY OF 17-BETA-ESTRADIOL
    LOFTSSON, T
    BODOR, N
    ACTA PHARMACEUTICA NORDICA, 1989, 1 (04): : 185 - 194